Findings

What do systematic reviews say?

4,752 questions · 6,648 findings · 688 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Laparoscopic treatment vs diagnostic laparoscopy

Quality of life EQ‐5D index summary (6 months) · women with endometriosis

1 finding from 1 review

Laparoscopic surgery for endometriosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Laparoscopic treatment vs diagnostic laparoscopy

Health‐related quality of life (mental) · women with endometriosis

1 finding from 1 review

Laparoscopic surgery for endometriosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Laparoscopic treatment vs diagnostic laparoscopy

Health‐related quality of life (physical) · women with endometriosis

1 finding from 1 review

Laparoscopic surgery for endometriosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Laparoscopic treatment vs diagnostic laparoscopy

Viable intrauterine Pregnancy · women with endometriosis

Laparoscopic treatment probably leads to higher viable intrauterine pregnancy confirmed by ultrasound compared with diagnostic laparoscopy (moderate certainty).

1 finding from 1 review

Laparoscopic surgery for endometriosis 2020 · Cochrane Headline outcomes only
OR 1.89 [1.25, 2.86]
3 studies · 528 participants
Moderate

Laparoscopic treatment vs diagnostic laparoscopy

Pregnancy loss: ectopic pregnancy per pregnancy · women with endometriosis

Laparoscopic treatment showed no clear difference in pregnancy loss: ectopic pregnancy per pregnancy compared with diagnostic laparoscopy (low certainty).

1 finding from 1 review

Laparoscopic surgery for endometriosis 2020 · Cochrane Headline outcomes only
OR 1.18 [0.1, 13.48]
1 study · 100 participants
Low

Laparoscopic treatment vs diagnostic laparoscopy

Miscarriage pregnancy rate · women with endometriosis

Laparoscopic treatment showed no clear difference in pregnancy loss: miscarriage per pregnancy compared with diagnostic laparoscopy (low certainty).

1 finding from 1 review

Laparoscopic surgery for endometriosis 2020 · Cochrane Headline outcomes only
OR 0.94 [0.35, 2.54]
2 studies · 112 participants
Low

LNG‐IUS vs non‐intrauterine progestogen

Regression of EH; by length of · endometrial hyperplasia

LNG‐IUS probably leads to higher regression of EH; by length of compared with non‐intrauterine progestogen (moderate certainty).

2 findings from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 2.94 [2.1, 4.13]
10 studies · 1108 participants
Moderate
Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 3.8 [1.75, 8.23]
1 study · 138 participants
Low

LNG vs no treatment

Adverse effects associated with hormones · women with endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LNG vs no treatment

Adverse effects requiring withdrawal/discontinuation of study medication · women with endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LNG vs no treatment

Satisfaction · women with endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LNG vs no treatment

Costs · women with endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LNG‐IUS vs non‐intrauterine progestogen

Hysterectomy; histologically and non‐histologically indicated · endometrial hyperplasia

LNG‐IUS may leads to lower hysterectomy; histologically and non‐histologically indicated compared with non‐intrauterine progestogen (low certainty).

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 0.26 [0.15, 0.46]
4 studies · 452 participants
Low

LNG‐IUS vs non‐intrauterine progestogen

Adverse effects associated with hormones:Bleeding/spotting Nausea Weight gain · endometrial hyperplasia

It is very uncertain whether LNG‐IUS changes adverse effects associated with hormones:Bleeding/spotting Nausea… compared with non‐intrauterine progestogen (very low certainty).

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 2.13 [1.33, 3.43]
3 studies · 428 participants
Very low

LNG‐IUS vs non‐intrauterine progestogen

Adverse effects requiring withdrawal/discontinuation of study medication · endometrial hyperplasia

LNG‐IUS showed no clear difference in withdrawal secondary to adverse effects compared with non‐intrauterine progestogen (low certainty).

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 0.41 [0.12, 1.35]
4 studies · 360 participants
Low

LNG‐IUS vs non‐intrauterine progestogen

Satisfaction with treatment · endometrial hyperplasia

It is very uncertain whether LNG‐IUS changes satisfaction with treatment compared with non‐intrauterine progestogen (very low certainty).

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 5.28 [2.51, 11.1]
2 studies · 202 participants
Very low

LNG vs no treatment

Regression of EH ‐ Short · women with endometrial hyperplasia

LNG may leads to higher regression of EH ‐ Short compared with no treatment (low certainty).

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
OR 78.41 [22.86, 268.97]
1 study · 190 participants
Low

LNG vs no treatment

Adverse effects associated with LNG‐IUS · women with endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LNG vs no treatment

Hysterectomy rate · women with endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.19 [0.92, 1.53]
1 study · 365 participants
Low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.25 [0.95, 1.64]
1 study · 517 participants
Low